The best way to answer that would be to investigate what income can be expected based on what we know and using some worst case scenarios for a fair analysis.
It was said that James Bay was going to be a replication of Mt Cattlin. If that is true then they would aim to have a production rate of 200,000tpa of spodumene per annum from each.
Assuming that spodumene pricing doesn't shift from $600 per tonne that would give a pre-cost income of $240 million US.
By around this time, I would imagine that there would be a ramp up of Sal de Vida (not full rate production 25kpta) taking place which would be producing a final grade of product. Price wise at the moment depends who you ask. Current pricing in China is ranging between $15,000 to $20,000 plus according to Anthony Tse in his SMI video. I predict up to $35,000 to $40,000 per tonne.
Some factors which will affect the share price are:
Calculating the predicted market cap based on:
- How many shares are in the market.
- Where is Sal De Vida up to?
- Does the company return to the HKSE listing?
- Has the company found a way to vertically integrate spodumene processing according to the Mitsubishi agreement.
- James Bay and Mt Cattlin are collaboratively producing 400,000tpa
- No inclusion of Sal De Vida including speculative market sentiment.
- Income based on 12.5% return before cost.
- No increase in the spodumene price ($600 US)
- Australian dollar still ranging close to 75c
- No spodumene processor or including further acquisitions.
Market cap approximately: $2.8 billion dollars. (That's in AUD)
- Forums
- ASX - By Stock
- GXY
- Lithium is in a strong bull market.
Lithium is in a strong bull market., page-7
-
- There are more pages in this discussion • 83 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GXY (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online